Resilience
Contract development and manufacturing organization (CDMO) providing end-to-end development and GMP manufacturing for biologics, vaccines, gene and cell therapies. Services include process & analytical development, cell line and master cell bank support, viral vector and cell therapy manufacturing, aseptic fill/finish, tech transfer and scale-up, and integrated testing and data platforms across a network of North American facilities.
Industries
Nr. of Employees
Very Large (1000+)
Resilience
La Jolla, California, United States, North America
Products
Alachua, FL biomanufacturing campus (Building G)
BSL-2 manufacturing and process/analytical development campus with approximately 92,000 sq ft single-use manufacturing space, dedicated utilities, EU grades A–D particulate controls, multiple GMP suites and cold/ultra-cold storage.
Boston process & analytical development and manufacturing facility
Commercially licensed PAD center combining process and analytical development with 10 × 2,000 L drug substance manufacturing capacity for biologics, vaccines, nucleic acids and gene therapy.
Alachua, FL biomanufacturing campus (Building G)
BSL-2 manufacturing and process/analytical development campus with approximately 92,000 sq ft single-use manufacturing space, dedicated utilities, EU grades A–D particulate controls, multiple GMP suites and cold/ultra-cold storage.
Boston process & analytical development and manufacturing facility
Commercially licensed PAD center combining process and analytical development with 10 × 2,000 L drug substance manufacturing capacity for biologics, vaccines, nucleic acids and gene therapy.
Services
Accelerated autologous CAR‑T manufacturing workflow designed to reduce manufacturing duration (example 3-day process) to enable faster clinical access and potential potency improvements.
Scalable viral vector manufacturing service for AAV and lentiviral vectors with reserved GMP batches and accelerated process deployment for clinical trials.
Integrated services covering cell line development, formulation, process development, analytical method development, and early clinical manufacturing to accelerate IND-enabling timelines.
High-dimensional multi-omics and single-cell genomics characterization and QC services to support cell therapy release testing, comparability and process optimization.
End-to-end manufacturing and assay platform for lentiviral-vector-based autologous T-cell therapies providing standardized unit operations, in-house release testing, digital batch records and regulatory support to accelerate clinical readiness.
Aseptic fill/finish, formulation and packaging services with automated isolator-based filling for vials and syringes and supporting quality and regulatory requirements.
Accelerated autologous CAR‑T manufacturing workflow designed to reduce manufacturing duration (example 3-day process) to enable faster clinical access and potential potency improvements.
Scalable viral vector manufacturing service for AAV and lentiviral vectors with reserved GMP batches and accelerated process deployment for clinical trials.
Integrated services covering cell line development, formulation, process development, analytical method development, and early clinical manufacturing to accelerate IND-enabling timelines.
High-dimensional multi-omics and single-cell genomics characterization and QC services to support cell therapy release testing, comparability and process optimization.
End-to-end manufacturing and assay platform for lentiviral-vector-based autologous T-cell therapies providing standardized unit operations, in-house release testing, digital batch records and regulatory support to accelerate clinical readiness.
Aseptic fill/finish, formulation and packaging services with automated isolator-based filling for vials and syringes and supporting quality and regulatory requirements.
Expertise Areas
- Biologics process and analytical development (PAD)
- Viral vector (AAV/LVV) process development and manufacturing
- Cell therapy development and manufacturing
- Autologous CAR‑T manufacturing and short-cycle processes
Key Technologies
- Single-use bioreactors (500 L–2,000 L)
- Continuous/perfusion upstream and continuous downstream processing
- Closed automated manufacturing systems with in-line monitoring
- Aseptic isolator-based filling
News & Updates
Exhibiting/attending event (Boston, MA, June 16–19, 2025).
Scheduled event in San Diego, CA (Nov 10–12, 2025).
Discussion of manufacturing cost drivers for cell therapies and technologies to reduce cost of goods sold, including next-generation characterization, automation and short-cycle approaches.
Description of a cloud-hosted lab supply chain tracking and operational data platform built on AWS to improve visibility and operational reliability.
Whitepaper describing a short-cycle CAR‑T manufacturing process intended to shorten conventional production timelines.
Webinar covering fill/finish capabilities and outsourced pharma capacity for sterile drug product manufacturing.
Exhibiting/attending event (Boston, MA, June 16–19, 2025).
Scheduled event in San Diego, CA (Nov 10–12, 2025).
Discussion of manufacturing cost drivers for cell therapies and technologies to reduce cost of goods sold, including next-generation characterization, automation and short-cycle approaches.
Description of a cloud-hosted lab supply chain tracking and operational data platform built on AWS to improve visibility and operational reliability.
Whitepaper describing a short-cycle CAR‑T manufacturing process intended to shorten conventional production timelines.
Webinar covering fill/finish capabilities and outsourced pharma capacity for sterile drug product manufacturing.